Alembic Pharma Q1 Profit Jumps 21%

  Published 10 months ago

Alembic Pharma posted 21% YoY PBT growth in Q1 FY26, led by strong global generics and specialty therapy performance.

  • Revenue grew 9.54% YoY to Rs 1,710.72 crore, with EBITDA up 20% and margin stable at 17%.
  • US Generics rose 13% YoY to Rs 523 crore; Ex-US markets surged 21% to Rs 328 crore on new launches.
  • India Branded Business grew 5% YoY; three new products launched amid steady therapy segment performance.

You might like these

RBI Holds Repo Rate Steady

India Bank Rates: May 2025 Update

India's Forex Reserves Dip to $685.729 Billion

Marico's 30% Revenue Rise on Hair Oils

HDFC Bank Q1 Profit at ₹16,260 Cr

M&M Group's May 2025 Sales & Exports Surge

Major Data Centre and CMS Contracts Won

News that matters the most ⚡